A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling

Bone

Volumn 46, Issue 1, 2010, Pages 49-63

  Peterson, Mark C ^a   Riggs, Matthew M ^b  

^a AMGEN INC   (United States)

^b Metrum Research Group LLC   (United States)

Author keywords

Bone remodeling; Endocrine regulation of calcium and bone; Parathyroid hormone; RANK RANKL OPG; Systems biology

Indexed keywords

CALCITRIOL; CALCIUM; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PHOSPHATE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BONE METABOLISM; BONE REMODELING; CALCIUM HOMEOSTASIS; MATHEMATICAL MODEL; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL;

BONE REMODELING; CALCITRIOL; CALCIUM; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PARATHYROID HORMONE; PHOSPHATES;

EID: 72149104599     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.08.053     Document Type: Article

References (78)

1. Raposo J.F., Sobrinho L.G., and Ferreira H.G. A minimal mathematical model of calcium homeostasis. J. Clin. Endocrinol. Metab. 87 (2002) 4330-4340
2. Lemaire V., Tobin F.L., Greller L.D., Cho C.R., and Suva L.J. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J. Theor. Biol. 229 (2004) 293-309
3. Bellido T., Ali A.A., Plotkin L.I., Fu Q., Gubrij I., Roberson P.K., et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J. Biol. Chem. 278 (2003) 50259-50272
4. Guyton A.C., Coleman T.G., Cowley Jr. A.W., Liard J.F., Norman Jr. R.A., and Manning Jr. R.D. Systems analysis of arterial pressure regulation and hypertension. Ann. Biomed. Eng. 1 (1972) 254-281
5. Forteo® teriparitide (rDNA origin) injection package insert (2004), Eli Lilly and Company, Indianapolis 1-22
6. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354 (2006) 821-831
7. Lewiecki E.M., Miller P.D., McClung M.R., Cohen S.B., Bolognese M.A., Liu Y., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J. Bone Miner. Res. 22 (2007) 1832-1841
8. Rix M., Andreassen H., Eskildsen P., Langdahl B., and Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 56 (1999) 1084-1093
9. Gibaldi M., and Perrier D. Pharmacokinetics (1982), Marcel Dekker, Inc., New York
10. Guo C.Y., Holland P.A., Jackson B.F., Hannon R.A., Rogers A., Harrison B.J., et al. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur. J. Endocrinol. 142 (2000) 451-459
11. Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., and Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 90 (2005) 135-141
12. Black D.M., Bilezikian J.P., Ensrud K.E., Greenspan S.L., Palermo L., Hue T., et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. 353 (2005) 555-565
13. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 26 (2005) 688-703
14. Kearns A.E., Khosla S., and Kostenuik P. RANKL and OPG regulation of bone remodeling in health and disease. Endocr. Rev. (2007)
15. Peterson M., Stouch B., Chen D., Baughman S., Holloway D., Bekker P., et al. A population PK/PD model describes the rapid, profound, and sustained suppression of urinary N-telopeptide following administration of AMG 162, a fully human monoclonal antibody against RANKL, to healthy postmenopausal women. AAPS J. (2004) 24
16. Heaney R.P., Dowell M.S., Hale C.A., and Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J. Am. Coll. Nutr. 22 (2003) 142-146
17. Heaney R.P., Barger-Lux M.J., Dowell M.S., Chen T.C., and Holick M.F. Calcium absorptive effects of vitamin D and its major metabolites. J. Clin. Endocrinol. Metab. 82 (1997) 4111-4116
18. Nordin B.E., Need A.G., Morris H.A., O'Loughlin P.D., and Horowitz M. Effect of age on calcium absorption in postmenopausal women. Am. J. Clin. Nutr 80 (2004) 998-1002
19. Pattanaungkul S., Riggs B.L., Yergey A.L., Vieira N.E., O'Fallon W.M., and Khosla S. Relationship of intestinal calcium absorption to 1,25-dihydroxyvitamin D [1,25(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action. J. Clin. Endocrinol. Metab 85 (2000) 4023-4027
20. Wolf R.L., Cauley J.A., Baker C.E., Ferrell R.E., Charron M., Caggiula A.W., et al. Factors associated with calcium absorption efficiency in pre- and perimenopausal women. Am. J. Clin. Nutr. 72 (2000) 466-471
21. Sheikh M.S., Schiller L.R., and Fordtran J.S. In vivo intestinal absorption of calcium in humans. Miner. Electrolyte. Metab. 16 (1990) 130-146
22. McCormick C.C. Passive diffusion does not play a major role in the absorption of dietary calcium in normal adults. J. Nutr. 132 (2002) 3428-3430
23. Parfitt A.M., Mundy G.R., and Martin T.J. Calcium homeostasis. Physiology and pharmacology of bone (1993), Springer-Verlag, Berlin 1-66
24. Nordin B.E.C. Calcium, phosphate and magnesium: clinical physiology and diagnostic procedures (1976), Edinburgh, Churchill Livingstone
25. Marenzana M., Shipley A.M., Squitiero P., Kunkel J.G., and Rubinacci A. Bone as an ion exchange organ: evidence for instantaneous cell-dependent calcium efflux from bone not due to resorption. Bone 37 (2005) 545-554
26. Weiss G.H., Goans R.E., Gitterman M., Abrams S.A., Vieira N.E., and Yergey A.L. A non-Markovian model for calcium kinetics in the body. J. Pharmacokinet. Biopharm. 22 (1994) 367-379
27. Frick K.K., LaPlante K., and Bushinsky D.A. RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. Am. J. Physiol. Renal. Physiol. 289 (2005) F1005-F1011
28. Copp D.H., McPherson G.D., and McIntosh H.W. Renal excretion of calcium in man: estimation of Tm-Ca. Metabolism 9 (1960) 680-685
29. Peacock M., and Nordin B.E. Tubular reabsorption of calcium in normal and hypercalciuric subjects. J. Clin. Pathol. 21 (1968) 353-358
30. Nordin B.E., and Peacock M. Role of kidney in regulation of plasma-calcium. Lancet 2 (1969) 1280-1283
31. Hoenderop J.G., Nilius B., and Bindels R.J. Calcium absorption across epithelia. Physiol. Rev 85 (2005) 373-422
32. Schmitt C.P., Schaefer F., Bruch A., Veldhuis J.D., Schmidt-Gayk H., Stein G., et al. Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium. J Clin. Endocrinol. Metab 81 (1996) 4236-4243
33. Brown E.M. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J. Clin. Endocrinol. Metab. 56 (1983) 572-581
34. Ramirez J.A., Goodman W.G., Gornbein J., Menezes C., Moulton L., Segre G.V., et al. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 76 (1993) 1489-1494
35. Goodman W.G., Veldhuis J.D., Belin T.R., Van Herle A.J., Juppner H., and Salusky I.B. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 83 (1998) 2765-2772
36. Malberti F., Farina M., and Imbasciati E. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol. Dial. Transplant. 14 (1999) 2398-2406
37. Indridason O.S., Heath III H., Khosla S., Yohay D.A., and Quarles L.D. Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int. 50 (1996) 1663-1671
38. Slatopolsky E., Brown A., and Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am. J. Kidney Dis. 37 (2001) S54-S57
39. Takahashi F., Denda M., Finch J.L., Brown A.J., and Slatopolsky E. Hyperplasia of the parathyroid gland without secondary hyperparathyroidism. Kidney Int. 61 (2002) 1332-1338
40. Slatopolsky E. The role of calcium, phosphorus and vitamin D metabolism in the development of secondary hyperparathyroidism. Nephrol. Dial. Transplant. 13 Suppl 3 (1998) 3-8
41. Nakanishi S., Yano S., Nomura R., Tsukamoto T., Shimizu Y., Shin J., et al. Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism. Nephrol. Dial. Transplant. 18 Suppl 3 (2003) iii47-iii49
42. Quarles L.D., Yohay D.A., Carroll B.A., Spritzer C.E., Minda S.A., Bartholomay D., et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 45 (1994) 1710-1721
43. Bieglmayer C., Prager G., and Niederle B. Kinetic analyses of parathyroid hormone clearance as measured by three rapid immunoassays during parathyroidectomy. Clin. Chem. 48 (2002) 1731-1738
44. Deftos L. Chapter 2. Calcium and phosphate homeostasis. In: Diseases of bone and mineral metabolism. Endotext.org.
45. Levi M., Popovtzer M., Berl T., and Bonventre J.V. Chapter 7. Disorders of phosphate balance. In: Schrier R.W. (Ed). Section I: Disorders of water, electrolytes, and acid-base: (2008). http://www.kidneyatlas.org/book1/adk1_07.pdf http://www.kidneyatlas.org/book1/adk1_07.pdf
46. Walton R.J., and Bijvoet O.L. Nomogram for derivation of renal threshold phosphate concentration. Lancet 2 (1975) 309-310
47. Uemura H., Irahara M., Yoneda N., Yasui T., Genjida K., Miyamoto K.I., et al. Close correlation between estrogen treatment and renal phosphate reabsorption capacity. J. Clin. Endocrinol. Metab. 85 (2000) 1215-1219
48. Dick I.M., Devine A., Beilby J., and Prince R.L. Effects of endogenous estrogen on renal calcium and phosphate handling in elderly women. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E430-E435
49. Laroche M. Phosphate, the renal tubule, and the musculoskeletal system. Joint Bone Spine 68 (2001) 211-215
50. Walser M. Protein-binding of inorganic phosphate in plasma of normal subjects and patients with renal disease. J. Clin. Invest. 39 (1960) 501-506
51. Karsdal M.A., Hjorth P., Henriksen K., Kirkegaard T., Nielsen K.L., Lou H., et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J. Biol. Chem. 278 (2003) 44975-44987
52. Fu Q., Jilka R.L., Manolagas S.C., and O'Brien C.A. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem. 277 (2002) 48868-48875
53. Ma Y.L., Cain R.L., Halladay D.L., Yang X., Zeng Q., Miles R.R., et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142 (2001) 4047-4054
54. Bellido T., Ali A.A., Gubrij I., Plotkin L.I., Fu Q., O'Brien C.A., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146 (2005) 4577-4583
55. Zhao M., Qiao M., Harris S.E., Oyajobi B.O., Mundy G.R., and Chen D. Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J. Biol. Chem. 279 (2004) 12854-12859
56. Jilka R.L., Weinstein R.S., Parfitt A.M., and Manolagas S.C. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J. Bone Miner. Res. 22 (2007) 1492-1501
57. Gilbert L., He X., Farmer P., Rubin J., Drissi H., van Wijnen A.J., et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J. Biol. Chem. 277 (2002) 2695-2701
58. Dallas S.L., Park-Snyder S., Miyazono K., Twardzik D., Mundy G.R., and Bonewald L.F. Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. J. Biol. Chem. 269 (1994) 6815-6821
59. Janssens K., ten D.P., Janssens S., and Van H.W. Transforming growth factor-beta1 to the bone. Endocr. Rev. 26 (2005) 743-774
60. Dallas S.L., Rosser J.L., Mundy G.R., and Bonewald L.F. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277 (2002) 21352-21360
61. Taipale J., Miyazono K., Heldin C.H., and Keski-Oja J. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J. Cell. Biol. 124 (1994) 171-181
62. Quinn J.M., Itoh K., Udagawa N., Hausler K., Yasuda H., Shima N., et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16 (2001) 1787-1794
63. Karsdal M.A., Larsen L., Engsig M.T., Lou H., Ferreras M., Lochter A., et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J. Biol. Chem. 277 (2002) 44061-44067
64. Jilka R.L., Weinstein R.S., Bellido T., Parfitt A.M., and Manolagas S.C. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res. 13 (1998) 793-802
65. Hock J.M., Krishnan V., Onyia J.E., Bidwell J.P., Milas J., and Stanislaus D. Osteoblast apoptosis and bone turnover. J. Bone Miner. Res. 16 (2001) 975-984
66. FDA, CDER. Forteo summary basis of approval. Forteo [teriparatide (rDNA origin)] injection. Company: Eli Lilly and Company. Application No. 021318. Approval Date: 11/26/2002. In; 2002.
67. Jia D., O'Brien C.A., Stewart S.A., Manolagas S.C., and Weinstein R.S. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147 (2006) 5592-5599
68. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
69. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20 (2005) 962-970
70. Food US, Drug A, Center for Drug E, Research. Forteo summary basis of approval. Forteo [teriparatide (rDNA origin)] injection. Company: Eli Lilly and Company. Application No. 021318. Approval Date: 11/26/2002. In; 2002.
71. Slovik D.M., Neer R.M., and Potts Jr. J.T. Short-term effects of synthetic human parathyroid hormone-(1-34) administration on bone mineral metabolism in osteoporotic patients. J Clin Invest 68 (1981) 1261-1271
72. Silverberg S.J., Shane E., Jacobs T.P., Siris E., and Bilezikian J.P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341 (1999) 1249-1255 Erratum in: N Engl J Med 2000 Jan 13;342(2):144
73. Kruse K., Kracht U., Wohlfart K., and Kruse U. Biochemical markers of bone turnover, intact serum parathyroid horn and renal calcium excretion in patients with pseudohypoparathyroidism and hypoparathyroidism before and during vitamin D treatment. Eur. J. Pediatr. 148 (1989) 535-539
74. Potter L.K., Greller L.D., Cho C.R., Nuttall M.E., Stroup G.B., Suva L.J., et al. Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics. Bone 37 (2005) 159-169
75. Kroll M.H. Parathyroid hormone temporal effects on bone formation and resorption. Bull. Math. Biol. 62 (2000) 163-188
76. Rattanakul C., Lenbury Y., Krishnamara N., and Wollkind D.J. Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy. Biosystems 70 (2003) 55-72
77. Komarova S.V. Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone. Endocrinology 146 (2005) 3589-3595
78. Pivonka P., Zimak J., Smith D.W., Gardiner B.S., Dunstan C.R., Sims N.A., et al. Model structure and control of bone remodeling: a theoretical study. Bone 43 (2008) 249-263